KNOW THE FACTS ABOUT FLU

KNOW THE FACTS ABOUT FLU

Flu places a significant burden on the health and economy of the United States.1

CDC estimates* that from October 1, 2024, through May 17, 2025, there have been1:

Between 47 and 82 Million Flu Illnesses
Between 21 and 37 Million Flu Medical Visits
Between 610,000 and 1.3 Million Flu Hospitalizations
Between 27,000 and 130,000 Flu Deaths
*Because influenza surveillance does not capture all cases of flu that occur in the US, CDC provides these estimated ranges to better reflect the larger burden of influenza. These estimates are calculated based on data collected through CDC's Influenza Hospitalization Surveillance Network (FluSurv-NET) and are preliminary.1

Annual flu vaccination goals remain unreached for both children and adults 18-64 years of age2-4

A 70% rate of annual flu vaccination in children 6 months to 17 years of age is the CDC's Healthy People 2030 goal, yet only 49.2% were vaccinated in the 2024-2025 season.2,3†

2024-2025 flu vaccine estimated coverage rates for children by age group3

Flu Vaccine Estimated Coverage Rates for Children from 6 Months to 4 Years Old
Flu Vaccine Estimated Coverage Rates for Children from 5 to 12 Years Old
Flu Vaccine Estimated Coverage Rates for Children from 13 to 17 Years Old

Additional options for influenza vaccination of children, including use of noninjectable vaccines, may help improve coverage5

CDC's Healthy People 2030 objective is a 70% rate of annual flu vaccination in adults 18 to 49 years of age, yet only 36.3% were vaccinated in the 2024-2025 season.2,4†

2024-2025 flu vaccination estimated coverage rates for adults by age group4

Flu Vaccine Estimated Coverage Rates for Adults from 18 to 49 Years Old

CDC recommends annual flu vaccination for everyone 6 months and older with any licensed, age-appropriate flu vaccine (IIV, RIV, LAIV, ccIIV, HD-IIV, allV). For those younger than 65 years, CDC does not preferentially recommend one vaccine over another.6

†Data published as of April 26, 2025.

aIIV=adjuvanted inactivated influenza vaccine; ccIIV=cell culture–based inactivated influenza vaccine; CDC=Centers for Disease Control and Prevention; HD-IIV=high-dose inactivated influenza vaccine; IIV=inactivated influenza vaccine; LAIV=live attenuated influenza vaccine; RIV=recombinant influenza vaccine.

IMPORTANT SAFETY INFORMATION

  • Do not administer FLUMIST to persons who have had a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or after a previous dose of any influenza vaccine, or to children and adolescents through 17 years of age who are receiving aspirin or aspirin-containing therapy
  • When administered in a healthcare setting, appropriate medical treatment must be immediately available to manage potential anaphylactic reactions. When self-administered or administered by a caregiver, immediate medical attention should be sought if the vaccine recipient experiences symptoms of an allergic reaction
  • In clinical trials, the risks of hospitalization and wheezing were increased in children younger than 2 years of age who received FLUMIST
  • Children younger than 5 years of age with recurrent wheezing and persons of any age with asthma may be at increased risk of wheezing following the administration of FLUMIST. FLUMIST has not been studied in persons with severe asthma or active wheezing
  • If Guillain-Barré syndrome has occurred within 6 weeks of any prior influenza vaccination, the decision to give FLUMIST should be based on careful consideration of potential benefits and risks
  • The effectiveness of FLUMIST has not been studied in immunocompromised persons
  • The safety of FLUMIST in individuals with underlying medical conditions that may predispose them to complications following wild-type influenza infection has not been established
  • FLUMIST may not protect all individuals receiving the vaccine
  • The most common solicited adverse reactions (≥10% in vaccine recipients and at least 5% greater than in placebo) reported after FLUMIST were runny nose or nasal congestion (ages 2-49 years), fever >100 °F (children ages 2-6 years), and sore throat (adult ages 18-49 years)

FLUMIST is a vaccine indicated for active immunization of persons 2 through 49 years of age for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUMIST is for intranasal administration only.

Please see full Prescribing Information, including Patient Information and Instructions for Use.

You may report side effects related to AstraZeneca products.